Shares of GeoVax Labs, a biotechnology company developing a monkeypox treatment, soared more than 50% early on Monday, August 19. The jump came after disappointing study results for another monkeypox treatment developed by SIGA Technologies. In addition, last week the World Health Organization (WHO) declared a public health emergency due to the monkeypox outbreak in Africa, boosting the stocks of vaccine and drug makers  for several days in a row.

Shares of monkeypox treatment maker GeoVax surge 50% amid news flow

Ahead of expected rate cuts, small-cap stocks have started to "show signs of life," <a href="https://www.fool.com/investing/stock-market/types-of-stocks/small-cap-stocks/">notes</a> the Motley Fool. It suggests that if the Fed achieves a "soft landing" — that is, lowering rates while avoiding a recession — small caps could outperform large caps and offers three of the best small-cap stocks to gain exposure to the potential outperformance.

The Motley Fool spotlights three small caps to buy ahead of expected Fed rate cuts

Sidus Space, a space company aiming to create a constellation of 3D-printed satellites, saw its shares <a href="https://www.nasdaq.com/market-activity/stocks/sidu">surge</a> more than 37% on Thursday, August 15. The gains were primarily driven by upbeat industry news, as satellite designer and manufacturer AST SpaceMobile reported strong <a href="https://feeds.issuerdirect.com/news-release.html?newsid=4653359431382393">results</a>, explained Freedom Broker senior analyst <strong>Yegor Tolmachev</strong>. He points out that AST uses Sidus technologies.

Sidus Space stock soars on positive industry news

Shares of fintech company DeFi Technologies <a href="https://www.nasdaq.com/market-activity/stocks/deftf">surged</a> more than 13% in OTC trading on Thursday, August 15. The company <a href="https://www.prnewswire.com/news-releases/defi-technologies-inc-announces-q2-2024-financial-results-achieving-its-strongest-financial-quarter-to-date-record-revenues-of-c-133-2-million-us-98-0-million-and-128-2-million-us-94-4-million-for-the-three-and-six-months-ended-june-30-2024-863755235.html#:~:text=DeFi%20Technologies%20Inc.-,Announces%20Q2%202024%20Financial%20Results%3A%20Achieving%20Its%20Strongest%20Financial%20Quarter,US%2453.2%20million)%20for%20the">reported</a> its "strongest financial quarter to date" and raised its full-year revenue guidance by approximately 50%.

Shares of fintech company DeFi Technologies jump after best quarter ever

Shares of Well Health Technologies, which owns outpatient health clinics in Canada and develops healthcare IT platforms, rose nearly 4% on the Toronto Stock Exchange today, Thursday, August 15. The company <a href="https://news-releases.well.company/news-releases/well-health-reports-record-results-for-q2-2024-driven-by-an-acceleration-in-organic-growth-and-raises-annual-guidance/">reported</a> record revenue and profit for the second quarter and raised its annual guidance.

Quotes on Canadian clinic owner Well rise on record revenue

"Essentially, we are interested in three things — a strong balance sheet, a record of success as a business, and the potential for a profitable future," <a href="https://www.royceinvest.com/people/chuck-royce">says</a> <strong>Chuck Royce</strong>, the long-time portfolio manager and the namesake of Royce Investment Partners. Over half a century ago, Royce was one of the first on Wall Street to focus on small-cap stocks. What principles underpin his investing?

How to invest in small caps: Five tips from Wall Street legend Chuck Royce

Shares of Ideanomics, an electric vehicle company, resumed their decline in OTC trading on Wednesday, August 14, after crashing over 60% and then rebounding 50% over the last few days. The stock initially plummeted after the U.S. SEC <a href="https://www.sec.gov/newsroom/press-releases/2024-94">announced</a> a settlement of fraud charges against Ideanomics and three of its senior executives. Without admitting or denying the charges, they agreed to pay a total of about $5 million.

EV company Ideanomics resumes losses in wake of fraud settlement

The fair value of BioStem Technologies, a manufacturer of perinatal tissue-based treatments, should be nearly 80% higher than the current share price, <a href="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_08132024_BSEM_Sorensen.pdf">according</a> to Zacks Small-Cap Research (Zacks SCR). BioStem has seen rapid growth recently, and its second-quarter 2024 earnings beat expectations, Zacks SCR <a href="https://scr.zacks.com/news/news-details/2024/BSEM-Revenues-are-Growing-Exponentially-/default.aspx">points out</a>. BioStem stock rose 8.4% in OTC trading on Tuesday, August 13.

Zacks spotlights stock of perinatal-tissue therapy developer as undervalued

Goldman Sachs Asset Management, which manages over $2 trillion in <a href="https://www.goldmansachs.com/careers/our-firm/asset-management/">assets</a>, is <a href="https://www.bloomberg.com/news/articles/2024-08-09/goldman-am-s-barrs-eyes-tech-picks-smallcaps-after-selloff?srnd=homepage-europe&amp;embedded-checkout=true&amp;sref=Y0jVLcFo">looking</a> to buy tech and small-cap stocks following the U.S. equities selloff and amid an expected normalization in rates.

Goldman Sachs AM eyes small caps after selloff

Shares of hearing implant developer Envoy Medical <a href="https://www.nasdaq.com/market-activity/stocks/coch">surged</a> almost 20% on Monday, August 12. Before the market opened, the company <a href="https://finance.yahoo.com/news/envoy-medical-reports-second-quarter-123400733.html">reported</a> its second-quarter 2024 results and announced that, after 18 months of preliminary research on its cochlear implant — which essentially replaces the function of the inner ear — it plans to move forward to a clinical trial.

Stock of hearing implant developer Envoy surges after clinical trial of new device announced

Sonoma Pharmaceuticals, which develops treatments for dermatological conditions and advanced wound care with its flagship product stabilized hypochlorous acid, saw its stock plunge almost 20% on Friday, August 9. The losses followed the <a href="https://ir.sonomapharma.com/press-releases/detail/412/sonoma-pharmaceuticals-reports-first-fiscal-quarter-2025">release</a> of worse than expected quarterly financial results.

Sonoma Pharmaceuticals shares plummet on disappointing earnings

Shares of VolitionRx, a company that develops early-detection tests for serious diseases, fell over 7% on Friday, August 9. This came after the company <a href="https://ir.volition.com/news-events/press-releases/detail/811/volitionrx-announces-pricing-of-up-to-21-5-million-registered-direct-offering">announced</a> a direct offering in which it plans to sell up to $21.5 million of new shares and warrants to an undisclosed investor.

Small caps